San Antonio, TX Clinical Trials Report — June 2026

For San Antonio residents considering participation in clinical research, June 2026 presents both urgent opportunities and a fresh wave of new studies. With a significant number of trials nearing their enrollment deadlines, prompt action is key for interested individuals.

A total of 57 clinical trials in San Antonio are slated to conclude within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 10 of these rapidly closing studies are still actively seeking participants without specific health conditions. These trials offer a chance to contribute to medical advancements before their enrollment windows close.

Act Now: Trials Nearing Their End

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various cancers and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (5 trials)
• Hepatic impairment (5 trials)
• Healthy (3 trials)
• Prostate cancer (2 trials)
• Type 2 diabetes (2 trials)
• Cancer (2 trials)
• Metastatic cancer (2 trials)
• Colorectal cancer (2 trials)
• Breast cancer (2 trials)
• Metastatic solid tumor (2 trials)

New Research Opportunities Emerge in San Antonio

This month, San Antonio saw the opening of 28 new clinical trials, a slight increase from the 26 trials that launched in May 2026. This brings the total number of actively recruiting clinical trials in San Antonio, TX, to 974 across 544 research facilities, underscoring the city's active research landscape.

June brings several high-profile new trials to San Antonio, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is initiating a notable Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This pivotal, multicenter, global, randomized, placebo-controlled, double-blind study aims for 3,600 participants to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for obesity or overweight.
• Also from Gasherbrum Bio, Inc., NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is a Phase 3 randomized, double-blind, placebo-controlled study for 1,100 participants living with overweight or obesity and Type 2 Diabetes Mellitus.
• Pfizer is sponsoring NCT07660198, "Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents." This Phase 3 study aims for 1,200 participants to learn about the safety and immune response of a new pneumococcal vaccine in children and adolescents.
• AstraZeneca is leading NCT07662135, "A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This Phase 3 study seeks 900 participants to evaluate the efficacy and safety of elecoglipron in adults with Type 2 Diabetes Mellitus and impaired renal function.
• RTI International is sponsoring NCT07625579, "Collaboration for Down Syndrome Progress (CDP)," a long-term observational study for 1,400 participants of all ages with Down syndrome to better understand their health, development, and everyday experiences.
• Convergent Genomics, Inc. is leading NCT07673016, "Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer." This prospective, multicenter observational study will collect urine and tumor biospecimens and associated clinical data from 2,500 patients undergoing evaluation, treatment, or surveillance for urothelial carcinoma.

New trials this month are exploring a range of conditions, with the most frequent being obesity (6 trials), overweight (5 trials), type 2 diabetes mellitus (2 trials), and chronic weight management (2 trials). Drug trials account for the largest share of new studies, with 17 new drug trials, followed by 4 'OTHER' type trials and 3 device trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. A total of 5 of the 28 new trials launched this month are actively seeking healthy volunteers. Across San Antonio, a total of 82 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

San Antonio's Leading Research Facilities

San Antonio is home to several leading research institutions and sites that consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• University of Texas Health Science Center at San Antonio (including "The University of Texas Health Science Center at San Antonio" and "UT Health San Antonio") leads with a combined total of 128 trials.
• NEXT Oncology (including "Next Oncology") is a significant contributor with a combined total of 64 trials.
• Research Site (37 trials)
• Children's Hospital of San Antonio (32 trials)
• Methodist Children's Hospital of South Texas (24 trials)
• START San Antonio (22 trials)
• GSK Investigational Site (13 trials)
• Texas Oncology - San Antonio (13 trials)
• Texas Dermatology and Laser Specialists (12 trials)

These institutions offer a broad spectrum of research, from comprehensive medical studies at the University of Texas Health Science Center at San Antonio to specialized oncology research at NEXT Oncology and Texas Oncology, and pediatric care at Children's Hospital of San Antonio and Methodist Children's Hospital of South Texas.

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 28 new trials launched this month, 24 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children. No new trials this month are exclusively for females or males.

Industry sponsors continue to drive a significant portion of research in San Antonio, initiating 20 of the new trials this month. Notable industry sponsors include Novo Nordisk A/S (3 trials), Gasherbrum Bio, Inc. (2 trials), AstraZeneca (2 trials), and Eli Lilly and Company (2 trials). Academic institutions, such as The University of Texas Health Science Center at San Antonio, also play a vital role, sponsoring 3 new trials.

Broadening Your Search: Nearby Texas Options

While San Antonio offers a robust array of clinical trial opportunities, individuals may also find options in other communities across Texas. Cities with active trials include Houston (46 trials), Dallas (24 trials), Austin (16 trials), Fort Worth (5 trials), McKinney (4 trials), El Paso (3 trials), Lampasas (3 trials), and Edinburg (3 trials).

As we move through June, San Antonio's dynamic research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.